🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vistagen CEO Shawn Singh comments on the recent positive results from the exploratory Phase 2A study of PH284, an investigational pherine nasal spray: bit.ly/40fWw0D $VTGN

Vistagen recently announced positive results from the Phase 2A study of PH284, an investigational pherine nasal spray. PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal. bit.ly/40fWw0D $VTGN

Recent positive results from our Phase 2A study of PH284 demonstrated improvements to subjective feeling of hunger as compared to placebo and appeared safe and well-tolerated in cancer patient population. For more information: bit.ly/40fWw0D $VTGN

Vistagen today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of #neuropathicpain. Read more: bit.ly/42I1juj $VTGN

Vistagen will host a conference call and webcast on Thursday, February 13 at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. Register here: bit.ly/3WOCAB8 $VTGN

Vistagen will host a conference call and webcast today, February 13 at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. Watch here: bit.ly/3WOCAB8 $VTGN

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update: bit.ly/3CLX4Uf $VTGN

Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview at the 45th Annual TD Cowen Healthcare Conference on Monday, March 3, 2025, at 2:30 p.m. ET. For more details: bit.ly/4i99rc3 $VTGN

Today's neuroscience breakthroughs are redefining mental health treatment, with our novel nose-to-brain neurocircuitry approach leading the charge. Our CEO, Shawn Singh joined the Power to the Patients podcast to discuss our pioneering approach. apple.co/4bladk2 $VTGN

Vistagen's CEO, Shawn Singh, will participate in a fireside chat during Stifel’s 2025 Virtual CNS Forum on Tuesday, March 18 at 12:00pm ET. For details, visit: bit.ly/4i6cthE $VTGN

Today at 12:00pm ET, Shawn Singh will participate in a fireside chat during Stifel’s 2025 Virtual CNS Forum. Watch the live webcast here: bit.ly/43IzAKC $VTGN

We’re proud to present at #ADAA2025 in Las Vegas, sharing research on the age of onset of SAD and the characteristics of young adults with and without SAD. Thanks to Anxiety and Depression Association of America for bringing the community together. #MentalHealthResearch #SocialAnxiety #Fasedienol

Vistagen's posters from the recent Anxiety and Depression Association of America Conference are now available on our website! Explore new insights into social anxiety disorder (SAD) and fasedienol clinical trials on our Publications page: bit.ly/3UOivtH #ADAA2025

Vistagen shared new data on social anxiety disorder at #ADAA2025. 31M+ U.S. adults affected, rising fastest among 18-22 y/o- yet treatment rates have decreased. The new data build on recent epidemiology findings from the 2024 NEI Congress: bit.ly/42QRXvW $VTGN